Clopidogrel compared with other antiplatelet agents for secondary prevention of vascular events in adults undergoing percutaneous coronary intervention: clinical and cost-effectiveness analyses.
作者信息
Chen Sy, Russell E, Banerjee S, Hutton B, Brown A, Asakawa K, McGahan L, Clark M, Severn M, Cox J, Sharma M
出版信息
CADTH Technol Overv. 2012;2(1):e2103. Epub 2012 Mar 1.
Abstract
摘要
相似文献
1
Clopidogrel compared with other antiplatelet agents for secondary prevention of vascular events in adults undergoing percutaneous coronary intervention: clinical and cost-effectiveness analyses.
CADTH Technol Overv. 2012;2(1):e2103. Epub 2012 Mar 1.
2
Prasugrel (Efient®) with percutaneous coronary intervention for treating acute coronary syndromes (review of TA182): systematic review and economic analysis.
Health Technol Assess. 2015 Apr;19(29):1-130. doi: 10.3310/hta19290.
3
Prevention of coronary heart disease with aspirin and clopidogrel: efficacy, safety, costs and cost-effectiveness.
Expert Opin Pharmacother. 2004 Mar;5(3):493-503. doi: 10.1517/14656566.5.3.493.
4
Clopidogrel versus Other Antiplatelet Agents for Secondary Prevention of Vascular Events in Adults with Acute Coronary Syndrome or Peripheral Vascular Disease: Clinical and Cost-Effectiveness Analyses.
CADTH Technol Overv. 2012;2(1):e2102. Epub 2012 Mar 1.
5
Clinical effectiveness and cost-effectiveness of clopidogrel and modified-release dipyridamole in the secondary prevention of occlusive vascular events: a systematic review and economic evaluation.
Health Technol Assess. 2004 Oct;8(38):iii-iv, 1-196. doi: 10.3310/hta8380.
6
Extended antiplatelet therapy with clopidogrel alone versus clopidogrel plus aspirin after completion of 9- to 12-month dual antiplatelet therapy for acute coronary syndrome patients with both high bleeding and ischemic risk. Rationale and design of the OPT-BIRISK double-blinded, placebo-controlled randomized trial.
Am Heart J. 2020 Oct;228:1-7. doi: 10.1016/j.ahj.2020.07.005. Epub 2020 Jul 9.
7
Cost-effectiveness analysis of pharmacogenomics-guided clopidogrel treatment in Spanish patients undergoing percutaneous coronary intervention.
Pharmacogenomics J. 2019 Oct;19(5):438-445. doi: 10.1038/s41397-019-0069-1. Epub 2019 Jan 16.
8
Republished: Antiplatelet therapy for secondary prevention of coronary artery disease.
Postgrad Med J. 2015 May;91(1075):284-90. doi: 10.1136/postgradmedj-2013-305399rep.
9
Randomized Comparisons of Double-Dose Clopidogrel or Adjunctive Cilostazol Versus Standard Dual Antiplatelet in Patients With High Posttreatment Platelet Reactivity: Results of the CREATIVE Trial.
Circulation. 2018 May 22;137(21):2231-2245. doi: 10.1161/CIRCULATIONAHA.117.030190. Epub 2018 Feb 2.
10
Cost-effectiveness of LOF-guided antiplatelet therapy in Chinese patients with acute coronary syndrome.
Pharmacogenomics. 2020 Jan;21(1):33-42. doi: 10.2217/pgs-2019-0050.
引用本文的文献
1
Evaluate Short-Term Outcomes of abciximab in ST-Segment Elevation Myocardial Infarction Patients Undergoing Percutaneous Coronary Intervention: A Meta-Analysis of Randomized Clinical Trials.
J Interv Cardiol. 2022 May 29;2022:3911414. doi: 10.1155/2022/3911414. eCollection 2022.
2
An Evaluation of the Cost-effectiveness of Comprehensive MTM Integrated with Point-of-Care Phenotypic and Genetic Testing for U.S. Elderly Patients After Percutaneous Coronary Intervention.
J Manag Care Spec Pharm. 2018 Feb;24(2):142-152. doi: 10.18553/jmcp.2018.24.2.142.
本文引用的文献
1
2009 Focused Updates: ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction (updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (updating the 2005 Guideline and 2007 Focused Update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.
Circulation. 2009 Dec 1;120(22):2271-306. doi: 10.1161/CIRCULATIONAHA.109.192663. Epub 2009 Nov 18.
2
Thienopyridine derivatives versus aspirin for preventing stroke and other serious vascular events in high vascular risk patients.
Cochrane Database Syst Rev. 2009 Oct 7;2009(4):CD001246. doi: 10.1002/14651858.CD001246.pub2.
3
Coronary artery stents: Part I. Evolution of percutaneous coronary intervention.
Anesth Analg. 2008 Aug;107(2):552-69. doi: 10.1213/ane.0b013e3181732049.
4
The primary and secondary prevention of coronary artery disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).
Chest. 2008 Jun;133(6 Suppl):776S-814S. doi: 10.1378/chest.08-0685.
5
Antithrombotic therapy for non-ST-segment elevation acute coronary syndromes: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).
Chest. 2008 Jun;133(6 Suppl):670S-707S. doi: 10.1378/chest.08-0691.
6
Cost-effectiveness of clopidogrel treatment in percutaneous coronary intervention: a European model based on a meta-analysis of the PCI-CURE, CREDO and PCI-CLARITY trials.
Curr Med Res Opin. 2008 Jul;24(7):2089-101. doi: 10.1185/03007990802222261. Epub 2008 Jun 10.
7
Incidence of death and acute myocardial infarction associated with stopping clopidogrel after acute coronary syndrome.
JAMA. 2008 Feb 6;299(5):532-9. doi: 10.1001/jama.299.5.532.
8
Oral antiplatelet therapy in secondary prevention of cardiovascular events: an assessment from the payer's perspective.
Pharmacoeconomics. 2007;25(12):1063-82. doi: 10.2165/00019053-200725120-00007.
9
Long-term cost-effectiveness of early and sustained clopidogrel therapy for up to 1 year in patients undergoing percutaneous coronary intervention after presenting with acute coronary syndromes without ST-segment elevation.
Am Heart J. 2006 Jan;151(1):219-27. doi: 10.1016/j.ahj.2005.02.044.
10
The cost-effectiveness of dual oral antiplatelet therapy following percutaneous coronary intervention: a Swedish analysis of the CREDO trial.
Eur J Health Econ. 2005 Dec;6(4):354-6, 358-62. doi: 10.1007/s10198-005-0323-0.
Zotero 插件